Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Oxygen-Guided transfusions may cut unnecessary blood use in heart surgery

NCT ID NCT05740059

Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether using a measure of oxygen in the blood (SvO2) to guide red blood cell transfusions during heart surgery could reduce how many patients receive transfusions. Over 600 adults undergoing on-pump cardiac surgery were randomly assigned to either standard restrictive transfusion or a strategy that only gave transfusions when both hemoglobin was low and SvO2 was below a threshold. The goal was to see if the SvO2-adjusted approach lowered transfusion rates without harming patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Red blood cell transfusion adjusted by central venous oxygen saturation (SvO2)
What this could lead to
If successful, this approach could reduce unnecessary blood transfusions during heart surgery, lowering risks and conserving blood supplies.
What could go wrong
This is a completed trial, but the strategy may not work for all patients or settings. Transfusion decisions based on SvO2 require additional monitoring and equipment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

676 people

The number who actually took part.

Started

Mar 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged above 18 years and under 85 years * Signed informed consent form from the patient or his/her close relative or surrogate (if present) before inclusion or when possible when the patient has been included in an emergency setting * Anaemic (Haemoglobin at inclusion ≤ 13 g/dL) * Operated on elective, on-pump cardiac surgery for : Coronary artery bypass graft (CABG); Aortic, mitral or tricuspid valve (replacement or repair); Ascending aorta;Left ventricle assistance device (LVAD) * Operated on urgent on-pump cardiac surgery for : CABG;Endocarditis;Aortic dissection; Heart transplantation * Subjects must be covered by public health insurance Exclusion Criteria: * Patient with no central venous catheter inserted in the superior vena cava * Pregnant or breast feeding patient * Subject unable to read or/and write * Participation in another interventional clinical trial or administration of an unapproved drug within the last 4 weeks before the screening date * Medical history of heparin-induced thrombocytopenia contraindicating heparin use during surgery * Persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric care and persons admitted to a health or social establishment for purposes other than research

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic valve disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aneurysm or dilatation of ascending aorta aortic valve disorder coronary artery disorder endocarditis heart failure mitral valve disorder tricuspid valve disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac surgery Cardiopulmonary bypass

Contacts and locations

Locations

  • Departement d'anesthésie et réanimation D - Arnaud de Villeneuve

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.